Bli medlem
Bli medlem

Du är här


co.don AG: co.don AG :Technology leader in chondrocyte regeneration increases share capital

co.don AG / co.don AG :Technology leader in chondrocyte regeneration increases
share capital. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
+++ Up to 2.6 million new shares to be issued at a subscription price of €1.90

+++ Funding for European approval
+++ Positive share performance

Teltow, 28.04.2014
- Capital increase at co.don AG: the biopharma company is issuing up to 2.6
million new shares at a price of €1.90, increasing the company's share
capital by up to €13,722,368. The subscription period begins on 28 April
2014. Subscription rights are being granted in a ratio of 17 to 4: existing
shareholders have the opportunity to buy four new shares at a price of €1.90
for every seventeen shares they already hold. Shareholders are also entitled
to place purchase orders for additional shares when they buy the new
securities. Other third parties can also order new shares on the same terms.
Distribution to new investors is being lead managed by SCHNIGGE
Wertpapierhandelsbank AG, Düsseldorf. The statutory subscription period ends
on 13 May 2014.

The price of the co.don AG share has performed well in recent months. Half a
year ago the share was trading at below one euro, but has now settled at
around the 3 euro mark. This distinct improvement is partly due to the
national marketing authorisation for the patented pharmaceutical
productco.don chondrosphere®
granted in December 2013 by the Paul Ehrlich Institute, the relevant federal
German authority, but also to increased communications between the biopharma
company and its shareholders. CEO Dr. Andreas Baltrusch will give
presentations on co.don AG at two capital market conferences in Munich
("Seven Sins/Seven Chances" on 30 April 2014 and "17th Munich Capital Market
Conference" on 21 May 2014) and at the "Small Cap Forum" on 7 May 2014 in
Frankfurt. Furthermore, shareholders will soon be able to address their
questions directly to the Executive Board every eight weeks - a hotline is
currently being set up for this purpose. "We are committed to sustainable,
transparent communications, which really add value for our shareholders and
for co.don AG", explained Dr. Baltrusch.

The proceeds of the capital increase are mainly to be used to carry out
further clinical trials to obtain central EU-wide approval for the cell-based
pharmaceutical productchondrosphere®
. This minimally invasive method of articular cartilage regeneration has been
applied successfully with some 6,000 patients to date in Germany.
Authorisation to market the product in the EU would substantially increase
the market potential open to the biopharma company. Experts estimate the
entire European market at around €1.2 billion annually. "Demand for our
chondrocyte regeneration product is growing rapidly on the German market and
preliminary work for the EU marketing authorisation is well advanced", said
Dr. Andreas Baltrusch with confidence.

The capital increase will also serve to prepare EU marketing authorisation for
the pharmaceutical productco.don chondrotransplant® DISC
- a method for treating vertebral cartilage defects with the patient's own
cells. So far, around 600 patients in Germany have been treated with the
co.don method following spinal disc herniation. An EU marketing authorisation
would also open up this promising market for the company from Teltow.

About co.don® AG:

The biopharmaceutical company is one of the leading specialists worldwide in
cell cultivation for the regenerative treatment of articular cartilage
defects and spinal disc defects
.In many cases the use of the company's patented pharmaceutical product can
avert the need for joint and spinal disc replacement surgery. Orthopaedic,
accident and neuro-surgeons are increasingly applying these regenerative
treatment methods. co.don® AG is listed on the Frankfurt Stock Exchange
(ISIN: DE000A1K0227). The company's Executive Board consists of Dr. Andreas
Baltrusch (CEO, CFO) and Ms Vilma Methner (COO, CSO).

Further information about co.don AG can be found at:

Press contact

Jens Secker

BrunoMedia GmbH | Dreikönigshof | Martinsstraße 17 | D-55116 Mainz

Tel +49 6131 930 28 33

Fax +49 6131 930 28 34



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: co.don AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.